KAI1/CD82 protein expression in primary prostate cancer and in BPH associated with cancer.
Current prognostic methods in primary prostate cancer cannot accurately identify patients with clinically significant disease at highest risk of developing metastases. This study examined KAI1/CD82 metastasis suppressor expression by quantitative immunohistochemical analysis of benign prostatic hyperplasia (BPH) and prostate cancer specimens. Altogether, prostate cancers exhibited significant KAI1 overexpression compared to BPH not associated with cancer (P = 0.022). Increased KAI1 expression in well and moderately differentiated cancers, above levels seen in BPH, with decreased expression in poorly differentiated cancers was observed. Interestingly, KAI1 expression in BPH associated with cancers was significantly higher than in BPH not associated with cancer (P = 0.009). Thus, KAI1 overexpression may restrain onset and early stage prostate cancer development, whilst its loss may predispose the patient to more aggressive cancer behaviour. Altered KAI1 expression in prostate cancers and BPH associated with cancer may have important diagnostic roles.
Lijovic
Marijana
M
Department of Medicine, The University of Melbourne, Vic., Australia.
Somers
Gino
G
Frauman
Albert G
AG
D000230:Adenocarcinoma / Q000378:metabolism* / Q000473:pathology; D015703:Antigens, CD; D002454:Cell Differentiation; D005786:Gene Expression Regulation; D006801:Humans; D007124:Immunoenzyme Techniques; D051861:Kangai-1 Protein; D008297:Male; D008562:Membrane Glycoproteins / Q000378:metabolism*; D009367:Neoplasm Staging; D011470:Prostatic Hyperplasia / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology; D011518:Proto-Oncogene Proteins
D015703:Antigens, CD; C497688:CD82 protein, human; D051861:Kangai-1 Protein; D008562:Membrane Glycoproteins; D011518:Proto-Oncogene Proteins